GlaxoSmithKline PLC ADR (GSK) financial statements

Healthcare · Drug Manufacturers - General · Market cap $93.4B

GlaxoSmithKline PLC ADR reported revenue of 32.7B GBP in fiscal 2025, up 1.8% a year over 9 years.

Net income was 5.7B GBP and the operating margin 24.3%, against 9.3% in 2016.

Free cash flow was 4.8B GBP, and the company returned 2.6B GBP in dividends and 1.4B GBP in net buybacks.

The diluted share count fell 16% over the period (buybacks).

Revenue and free cash flow

Fiscal years, $ billions (GBP).

Embed this chart

Free to use in articles and newsletters with the source line. Paste this HTML:

<iframe src="https://investingly.io/embed/GSK/financials" width="100%" height="330" style="border:0;max-width:680px" title="GlaxoSmithKline PLC ADR revenue and free cash flow" loading="lazy"></iframe>
<p style="font-size:13px">Source: <a href="https://investingly.io/stocks/GSK/financials">GlaxoSmithKline PLC ADR financials</a> on Investingly</p>

Income statement

Fiscal years, in GBP, from GlaxoSmithKline PLC ADR's 10-K filings with the SEC.

Fiscal year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	27.9B GBP	30.2B GBP	30.8B GBP	33.8B GBP	24.4B GBP	24.7B GBP	29.3B GBP	30.3B GBP	31.4B GBP	32.7B GBP
Cost of revenue	9.3B GBP	10.3B GBP	10.2B GBP	11.9B GBP	7.9B GBP	8.2B GBP	9.6B GBP	8.6B GBP	9.0B GBP	9.0B GBP
Gross profit	18.6B GBP	19.8B GBP	20.6B GBP	21.9B GBP	16.4B GBP	16.5B GBP	19.8B GBP	21.8B GBP	22.3B GBP	23.6B GBP
Research and development	3.6B GBP	4.5B GBP	3.9B GBP	4.6B GBP	4.8B GBP	5.0B GBP	5.5B GBP	6.2B GBP	6.4B GBP	7.5B GBP
Selling, general and admin	9.4B GBP	9.7B GBP	9.9B GBP	11.4B GBP	7.4B GBP	7.1B GBP	8.4B GBP	9.4B GBP	11.0B GBP	9.1B GBP
Operating income	2.6B GBP	4.1B GBP	5.5B GBP	7.0B GBP	6.0B GBP	4.4B GBP	6.4B GBP	6.7B GBP	4.0B GBP	7.9B GBP
Interest expense	736M GBP	734M GBP	798M GBP	912M GBP	888M GBP	775M GBP	912M GBP	792M GBP	669M GBP	701M GBP
Pre-tax income	1.9B GBP	3.5B GBP	4.8B GBP	6.2B GBP	5.2B GBP	3.6B GBP	5.6B GBP	6.1B GBP	3.5B GBP	7.4B GBP
Income tax	877M GBP	1.4B GBP	754M GBP	953M GBP	67M GBP	83M GBP	707M GBP	756M GBP	526M GBP	1.1B GBP
Net income	912M GBP	1.5B GBP	3.6B GBP	4.6B GBP	5.7B GBP	4.4B GBP	15.0B GBP	4.9B GBP	2.6B GBP	5.7B GBP
EPS (diluted)	0.19 GBP	0.31 GBP	0.73 GBP	0.93 GBP	1.43 GBP	1.08 GBP	3.66 GBP	1.20 GBP	0.62 GBP	1.39 GBP
Diluted shares	4.91B	4.94B	4.97B	5.02B	4.03B	4.05B	4.08B	4.11B	4.14B	4.12B
Gross margin	66.7%	65.7%	66.8%	64.9%	67.4%	66.9%	67.4%	71.8%	71.2%	72.4%
Operating margin	9.3%	13.5%	17.8%	20.6%	24.6%	17.6%	21.9%	22.2%	12.8%	24.3%
Net margin	3.3%	5.1%	11.8%	13.8%	23.6%	17.8%	51.0%	16.2%	8.2%	17.5%

Balance sheet

Fiscal years, in GBP, from GlaxoSmithKline PLC ADR's 10-K filings with the SEC.

Fiscal year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Cash and short-term investments	4.9B GBP	3.8B GBP	3.9B GBP	4.7B GBP	6.3B GBP	4.3B GBP	3.7B GBP	2.9B GBP	3.9B GBP	3.4B GBP
Receivables	6.0B GBP	6.0B GBP	6.4B GBP	7.2B GBP	7.0B GBP	7.9B GBP	7.1B GBP	7.4B GBP	6.8B GBP	7.5B GBP
Inventory	5.1B GBP	5.6B GBP	5.5B GBP	5.9B GBP	6.0B GBP	5.8B GBP	5.1B GBP	5.5B GBP	5.7B GBP	5.9B GBP
Total current assets	16.7B GBP	15.9B GBP	16.9B GBP	19.5B GBP	20.2B GBP	18.7B GBP	20.8B GBP	18.6B GBP	17.0B GBP	17.5B GBP
Property, plant and equipment	10.8B GBP	10.9B GBP	11.1B GBP	10.3B GBP	10.2B GBP	9.9B GBP	8.9B GBP	9.0B GBP	9.2B GBP	9.3B GBP
Goodwill	6.0B GBP	5.7B GBP	5.8B GBP	10.6B GBP	10.6B GBP	10.6B GBP	7.0B GBP	6.8B GBP	7.0B GBP	7.0B GBP
Total assets	59.1B GBP	56.4B GBP	58.1B GBP	79.7B GBP	80.4B GBP	79.1B GBP	60.1B GBP	59.0B GBP	59.5B GBP	61.1B GBP
Total current liabilities	19.0B GBP	26.6B GBP	22.5B GBP	24.1B GBP	22.1B GBP	23.7B GBP	22.8B GBP	21.1B GBP	21.7B GBP	21.4B GBP
Long-term debt	14.7B GBP	14.3B GBP	20.3B GBP	23.6B GBP	23.4B GBP	20.6B GBP	17.0B GBP	15.2B GBP	14.6B GBP	14.7B GBP
Total liabilities	54.1B GBP	52.9B GBP	54.4B GBP	61.3B GBP	59.6B GBP	57.8B GBP	50.0B GBP	46.2B GBP	46.4B GBP	45.2B GBP
Shareholders' equity	1.1B GBP	-68M GBP	3.8B GBP	11.4B GBP	14.6B GBP	15.1B GBP	10.6B GBP	13.3B GBP	13.7B GBP	16.4B GBP
Net debt	13.9B GBP	13.3B GBP	22.2B GBP	25.8B GBP	20.9B GBP	19.9B GBP	17.3B GBP	15.1B GBP	13.1B GBP	14.3B GBP

Cash flow

Fiscal years, in GBP, from GlaxoSmithKline PLC ADR's 10-K filings with the SEC.

Fiscal year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating cash flow	6.5B GBP	6.9B GBP	8.4B GBP	8.0B GBP	8.4B GBP	8.0B GBP	7.4B GBP	6.8B GBP	6.6B GBP	7.7B GBP
Capital spending	2.4B GBP	2.2B GBP	1.8B GBP	2.2B GBP	1.9B GBP	2.7B GBP	2.3B GBP	2.3B GBP	3.0B GBP	3.0B GBP
Free cash flow	4.1B GBP	4.7B GBP	6.6B GBP	5.9B GBP	6.5B GBP	5.3B GBP	5.1B GBP	4.4B GBP	3.6B GBP	4.8B GBP
Stock-based compensation	319M GBP	333M GBP	360M GBP	365M GBP	337M GBP	343M GBP	346M GBP	307M GBP	344M GBP	374M GBP
Dividends paid	4.8B GBP	-3.9B GBP	3.9B GBP	4.0B GBP	4.0B GBP	4.0B GBP	3.5B GBP	2.2B GBP	2.4B GBP	2.6B GBP
Share buybacks (net)	—	—	—	—	—	—	—	0 GBP	0 GBP	-1.4B GBP
Net borrowing	—	2.2B GBP	10.1B GBP	4.8B GBP	3.3B GBP	0 GBP	-5.6B GBP	-2.0B GBP	-540M GBP	579M GBP
Free cash flow margin	14.9%	15.6%	21.5%	17.4%	26.7%	21.5%	17.5%	14.6%	11.4%	14.6%
Dividends per share	0.99 GBP	0.79 GBP	0.79 GBP	0.79 GBP	0.99 GBP	0.99 GBP	0.85 GBP	0.55 GBP	0.59 GBP	0.62 GBP

Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for GSK.

Open GSK in Investingly

Questions

What was GlaxoSmithKline PLC ADR's revenue in 2025?

32.7B GBP in fiscal 2025, from its 10-K filing.

How much free cash flow does GlaxoSmithKline PLC ADR generate?

4.8B GBP in fiscal 2025 (operating cash flow minus capital spending).

From GlaxoSmithKline PLC ADR's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.